van der Heide A, Wessel M, Papadopetraki D, Geurts D, van Prooije T, Gommans F
Ann Neurol. 2024; 97(4):741-752.
PMID: 39707791
PMC: 11889531.
DOI: 10.1002/ana.27159.
Zhou J, van der Heijden M, Salazar Leon L, Lin T, Miterko L, Kizek D
Cells. 2022; 11(23).
PMID: 36497147
PMC: 9740691.
DOI: 10.3390/cells11233889.
Zesiewicz T, Vega J, Gooch C, Ghanekar S, Huang Y, Bezchlibnyk Y
Mov Disord Clin Pract. 2022; 9(6):728-734.
PMID: 35937491
PMC: 9346245.
DOI: 10.1002/mdc3.13492.
Castonguay C, Liao C, Khayachi A, Liu Y, Medeiros M, Houle G
NPJ Genom Med. 2022; 7(1):46.
PMID: 35927430
PMC: 9352876.
DOI: 10.1038/s41525-022-00318-9.
Snell H, Vitenzon A, Tara E, Chen C, Tindi J, Jordan B
Sci Adv. 2022; 8(16):eabh2675.
PMID: 35442745
PMC: 9020779.
DOI: 10.1126/sciadv.abh2675.
Anti-Tremor Action of Subtype Selective Positive Allosteric Modulators of GABA Receptors in a Rat Model of Essential Tremors.
Amrutkar D, Dyhring T, Jacobsen T, Larsen J, Sandager-Nielsen K
Cerebellum. 2020; 19(2):265-274.
PMID: 31989440
DOI: 10.1007/s12311-020-01106-w.
Essential tremor.
Zesiewicz T, Kuo S
BMJ Clin Evid. 2015; 2015.
PMID: 26678329
PMC: 4681313.
Linking Essential Tremor to the Cerebellum: Neurochemical Evidence.
Marin-Lahoz J, Gironell A
Cerebellum. 2015; 15(3):243-52.
PMID: 26498765
DOI: 10.1007/s12311-015-0735-z.
Update on treatment of essential tremor.
Zesiewicz T, Shaw J, Allison K, Staffetti J, Okun M, Sullivan K
Curr Treat Options Neurol. 2013; 15(4):410-23.
PMID: 23881742
DOI: 10.1007/s11940-013-0239-4.
Treatment of essential tremor: a systematic review of evidence and recommendations from the Italian Movement Disorders Association.
Zappia M, Albanese A, Bruno E, Colosimo C, Filippini G, Martinelli P
J Neurol. 2012; 260(3):714-40.
PMID: 22886006
DOI: 10.1007/s00415-012-6628-x.
Essential tremor.
Ferreira J, Sampaio C
BMJ Clin Evid. 2009; 2007.
PMID: 19454072
PMC: 2943813.
Use of propranolol in treating tardive dyskinesia.
Einarson T
Can Med Assoc J. 1981; 124(10):1260, 1262.
PMID: 7237311
PMC: 1705432.
Metoprolol and propranolol in essential tremor: a double-blind, controlled study.
Calzetti S, Findley L, Gresty M, Perucca E, Richens A
J Neurol Neurosurg Psychiatry. 1981; 44(9):814-9.
PMID: 7031187
PMC: 491142.
DOI: 10.1136/jnnp.44.9.814.
Essential tremor.
Murray T
Can Med Assoc J. 1981; 124(12):1559-65, 1570.
PMID: 7018658
PMC: 1862527.
CFS hydroxylase cofactor levels in some neurological diseases.
Williams A, Levine R, Chase T, Lovenberg W, Calne D
J Neurol Neurosurg Psychiatry. 1980; 43(8):735-8.
PMID: 6448917
PMC: 490647.
DOI: 10.1136/jnnp.43.8.735.
Beta-adrenoreceptor mechanisms in essential tremor; a double-blind placebo controlled trial of metoprolol, sotalol and atenolol.
Leigh P, Jefferson D, Twomey A, Marsden C
J Neurol Neurosurg Psychiatry. 1983; 46(8):710-5.
PMID: 6310053
PMC: 1027523.
DOI: 10.1136/jnnp.46.8.710.
Beta-adrenoreceptor mechanisms in essential tremor: a comparative single dose study of the effect of a non-selective and a beta-2 selective adrenoreceptor antagonist.
Cleeves L, Findley L
J Neurol Neurosurg Psychiatry. 1984; 47(9):976-82.
PMID: 6148382
PMC: 1028001.
DOI: 10.1136/jnnp.47.9.976.
Use of beta-adrenergic receptor blocking drugs in psychiatry.
Whitlock F, Price J
Drugs. 1974; 8(2):109-24.
PMID: 4154835
DOI: 10.2165/00003495-197408020-00004.
Quantitative study of action tremor in various patient categories.
Francolini P, Giaquinto S, Massi G, Nolfe G
Ital J Neurol Sci. 1985; 6(1):67-73.
PMID: 3997464
DOI: 10.1007/BF02229220.
A comparison of primidone, propranolol, and placebo in essential tremor, using quantitative analysis.
Gorman W, Cooper R, Pocock P, Campbell M
J Neurol Neurosurg Psychiatry. 1986; 49(1):64-8.
PMID: 3514797
PMC: 1028650.
DOI: 10.1136/jnnp.49.1.64.